Earnings Call Summary | Panbela Therapeutics(PBLA.US) Q4 2023 Earnings Conference
Earnings Call Summary | Panbela Therapeutics(PBLA.US) Q4 2023 Earnings Conference
The following is a summary of the Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript:
以下是Panbela Therapeutics, Inc.(PBLA)2023年第四季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Panbela's general and administrative expenses were down to $0.9 million due to lower professional fees.
Research and development expenses increased to $6.1 million primarily due to increased activity in the ASPIRE trial.
Net loss for the quarter was $6.5 million, an increase from $4.7 million in the previous year.
Cash at the end of the quarter was $2.6 million, not including the $9 million from a public offering closed in January.
由於專業費用降低,Panbela的一般和管理費用降至90萬美元。
研發費用增加到610萬美元,這主要是由於ASPIRE試驗活動的增加。
該季度的淨虧損爲650萬美元,高於去年的470萬美元。
本季度末的現金爲260萬美元,不包括1月份完成的公開發行產生的900萬美元。
Business Progress:
業務進展:
The ASPIRE trial for metastatic pancreatic ductal adenocarcinoma achieved over 50% faster enrollment than projected.
Plans are underway to advance the FAP program in collaboration with the FDA and EMA.
The PACES trial cleared a planned futility analysis and completed its enrollment, with data expected by the second half of 2026.
Panbela divested assets from the Eflornithine Pediatric Neuroblastoma Program, with anticipated non-dilutive payments of up to $9.5 million.
Panbela has multiple trials in phase 1 and 2 to explore polyamine-targeted therapies in various cancers.
A collaboration with The Johns Hopkins University School of Medicine for a Phase 1 or Phase 2 program is being planned, with program commencement expected in the first half of the year.
針對轉移性胰腺導管腺癌的ASPIRE試驗的入組速度比預期快50%以上。
正在計劃與美國食品藥品管理局和歐洲藥品管理局合作推進FAP計劃。
PACES試驗批准了計劃中的徒勞分析並完成了註冊,數據預計將於2026年下半年公佈。
Panbela從Eflornithine小兒神經母細胞瘤項目中剝離了資產,預計非攤薄付款高達950萬美元。
Panbela在1期和2期進行了多項試驗,以探索針對各種癌症的聚胺靶向療法。
正在計劃與約翰·霍普金斯大學醫學院合作實施第一階段或第二階段的項目,該項目預計將於今年上半年啓動。
More details: Panbela Therapeutics IR
更多詳情: Panbela 治療公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。